License was iBio’s largest revenue line in fiscal 2022, bringing in $1.80M of $2.38M (76%).
| Income Statement Location | FY 2021 | FY 2022 |
|---|---|---|
| License | — | $1.80M |
| Bioprocessing (Ibio Cdmo) | $2.37M | $583.00K |
| Total | $2.37M | $2.38M |
iBio brought in $2.38M from its two revenue lines in fiscal 2022, the year ended June 30, 2022. iBio regrouped these revenue lines after fiscal 2021, so the total does not compare directly with that year's $2.37M. License was the largest at $1.80M (75.5%), ahead of Bioprocessing (Ibio Cdmo) at $583.00K (24.5%).
iBio began breaking out License in fiscal 2022, when it brought in $1.80M.
Biopharmaceuticals (Ibio, Inc.) was iBio’s largest segment in fiscal 2022, bringing in $1.88M of $2.38M (79%).
| Segment | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 |
|---|---|---|---|---|---|---|---|
| Biopharmaceuticals (Ibio, Inc.) | — | $1.55M | $1.10M | $1.88M | |||
| Ibio Inc | $2.02M | — | — | — | |||
| Ibio, Inc | — | — | — | — | |||
| Bioprocessing (Ibio Cdmo) | — | $92.00K | $1.27M | $499.00K | |||
| Ibio Cdmo | — | — | — | — | |||
| Total | $2.02M | $1.64M | $2.37M | $2.38M |
iBio brought in $2.38M from its two segments in fiscal 2022, the year ended June 30, 2022. That was up 0.5% from $2.37M in fiscal 2021. Biopharmaceuticals (Ibio, Inc.) was the largest at $1.88M (79.1%), ahead of Bioprocessing (Ibio Cdmo) at $499.00K (20.9%).
Compared with fiscal 2021, Biopharmaceuticals (Ibio, Inc.) grew 71.6% to $1.88M, while Bioprocessing (Ibio Cdmo) fell 60.8% to $499.00K.
iBio began breaking out Biopharmaceuticals (Ibio, Inc.) in fiscal 2020 and Bioprocessing (Ibio Cdmo) in fiscal 2020. iBio stopped reporting Ibio Inc as a separate segment after fiscal 2019, when it brought in $2.02M.
Transferred At Point In Time was iBio’s largest revenue line in fiscal 2020, bringing in $1.49M of $1.64M (91%).
| Timing of Transfer of Good or Service | FY 2019 | FY 2020 |
|---|---|---|
| Transferred Over Time | — | $147.00K |
| Recognized Over Time | $1.85M | — |
| Transferred At Point In Time | — | $1.49M |
| Recognized At A Point In Time | $170.00K | — |
| Total | $2.02M | $1.64M |
iBio brought in $1.64M from its two revenue lines in fiscal 2020, the year ended June 30, 2020. iBio regrouped these revenue lines after fiscal 2019, so the total does not compare directly with that year's $2.02M. Transferred At Point In Time was the largest at $1.49M (91.0%), ahead of Transferred Over Time at $147.00K (9.0%).
iBio began breaking out Transferred Over Time in fiscal 2020 and Transferred At Point In Time in fiscal 2020. iBio stopped reporting Recognized Over Time ($1.85M in fiscal 2019) and Recognized At A Point In Time ($170.00K in fiscal 2019) as separate revenue lines.
iBio (IBIO) reports its revenue by income statement location, by segment and by timing of transfer of good or service. In fiscal 2022, License was its largest revenue line, bringing in $1.80M (75.5% of the total), followed by Bioprocessing (Ibio Cdmo) at $583.00K (24.5%).
License was iBio's largest revenue line in fiscal 2022, bringing in $1.80M, or 75.5% of the $2.38M total across its two revenue lines.
Biopharmaceuticals (Ibio, Inc.) was iBio's largest segment in fiscal 2022, bringing in $1.88M, or 79.1% of the $2.38M total across its two segments.
Biopharmaceuticals (Ibio, Inc.) grew faster than Bioprocessing (Ibio Cdmo) in fiscal 2022, up 71.6% from $1.10M to $1.88M. Bioprocessing (Ibio Cdmo) fell 60.8% to $499.00K.
Every figure comes from iBio's annual financial filings, as reported. Each line keeps the name iBio gives it, and years follow its fiscal calendar.
iBio's revenue by income statement location goes back to fiscal 2021, with figures through fiscal 2022. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.